These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 2741340

  • 21. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
    Hashizume M, Takashima A, Iwasaki M.
    J Virol; 2024 Jun 13; 98(6):e0057824. PubMed ID: 38767352
    [Abstract] [Full Text] [Related]

  • 22. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, Whitton JL.
    Virology; 2005 Apr 25; 335(1):87-98. PubMed ID: 15823608
    [Abstract] [Full Text] [Related]

  • 23. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y, Iwasaki M, Motooka D, Liu DX, Yu S, Cooper K, Hart R, Adams R, Burdette T, Postnikova EN, Kurtz J, St Claire M, Ye C, Kuhn JH, Martínez-Sobrido L, de la Torre JC.
    mBio; 2020 Mar 24; 11(2):. PubMed ID: 32209677
    [Abstract] [Full Text] [Related]

  • 24. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
    Jahrling PB.
    J Med Virol; 1983 Mar 24; 12(2):93-102. PubMed ID: 6619814
    [Abstract] [Full Text] [Related]

  • 25. Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies.
    Hufert FT, Lüdke W, Schmitz H.
    Arch Virol; 1989 Mar 24; 106(3-4):201-12. PubMed ID: 2476109
    [Abstract] [Full Text] [Related]

  • 26. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R, Ticer A, Brasky K, Lukashevich IS.
    Virology; 2006 Feb 20; 345(2):299-304. PubMed ID: 16412488
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
    Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A.
    Virology; 1998 Nov 10; 251(1):28-37. PubMed ID: 9813200
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein.
    Sumner JW, Fekadu M, Shaddock JH, Esposito JJ, Bellini WJ.
    Virology; 1991 Aug 10; 183(2):703-10. PubMed ID: 1840709
    [Abstract] [Full Text] [Related]

  • 32. Recombinant vaccinia viruses which express MHV-JHM proteins: protective immune response and the influence of vaccination on coronavirus-induced encephalomyelitis.
    Flory E, Stühler A, Wege H, Siddell S, Wege H.
    Adv Exp Med Biol; 1993 Aug 10; 342():401-6. PubMed ID: 8209761
    [Abstract] [Full Text] [Related]

  • 33. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies.
    Esposito J, Brechling K, Baer G, Moss B.
    Virus Genes; 1987 Nov 10; 1(1):7-21. PubMed ID: 3508340
    [Abstract] [Full Text] [Related]

  • 34. Baculovirus expression of the glycoprotein gene of Lassa virus and characterization of the recombinant protein.
    Hummel KB, Martin ML, Auperin DD.
    Virus Res; 1992 Sep 01; 25(1-2):79-90. PubMed ID: 1413995
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
    Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS.
    Vaccine; 2011 Feb 01; 29(6):1248-57. PubMed ID: 21145373
    [Abstract] [Full Text] [Related]

  • 37. Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection.
    Hertig C, Pye AD, Hyatt AD, Davis SS, McWilliam SM, Heine HG, Walker PJ, Boyle DB.
    J Gen Virol; 1996 Apr 01; 77 ( Pt 4)():631-40. PubMed ID: 8627251
    [Abstract] [Full Text] [Related]

  • 38. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF.
    Virology; 1997 Dec 22; 239(2):389-401. PubMed ID: 9434729
    [Abstract] [Full Text] [Related]

  • 39. Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses.
    Romero CH, Barrett T, Chamberlain RW, Kitching RP, Fleming M, Black DN.
    Virology; 1994 Oct 22; 204(1):425-9. PubMed ID: 8091673
    [Abstract] [Full Text] [Related]

  • 40. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ.
    Nat Commun; 2018 Oct 11; 9(1):4223. PubMed ID: 30310067
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.